FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:521-523 February 2, 2006 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Type 1 diabetes mellitus is one medical condition likely to benefit from stem-cell therapy: insulin-secreting pancreatic beta cells derived from stem cells — pending availability — could be transplanted into patients and help maintain blood glucose homeostasis. The relative success of the transplantation of cadaveric beta cells into patients with type 1 diabetes¹ provides support for this approach. The theoretically unlimited supply of beta cells derived from stem cells could translate into a better life for countless patients. Although there has been much discussion about the particulars of such transplantations, including the optimal delivery site, the composition of the transplanted . . . [Full Text of this Article]

Source Information

From the Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.